Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Paton NI, et al. Among authors: kityo c. Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8. Lancet HIV. 2017. PMID: 28495562 Free PMC article. Clinical Trial.
Resistance to antiretroviral therapy among patients in Uganda.
Weidle PJ, Kityo CM, Mugyenyi P, Downing R, Kebba A, Pieniazek D, Respess R, Hertogs K, De Vroey V, Dehertogh P, Bloor S, Larder B, Lackritz E. Weidle PJ, et al. Among authors: kityo cm. J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):495-500. doi: 10.1097/00126334-200104150-00017. J Acquir Immune Defic Syndr. 2001. PMID: 11391172
Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.
Gao Y, Paxinos E, Galovich J, Troyer R, Baird H, Abreha M, Kityo C, Mugyenyi P, Petropoulos C, Arts EJ. Gao Y, et al. Among authors: kityo c. J Virol. 2004 May;78(10):5390-401. doi: 10.1128/jvi.78.10.5390-5401.2004. J Virol. 2004. PMID: 15113918 Free PMC article.
Stevens - Johnson syndrome due to nevirapine.
Namayanja GK, Nankya JM, Byamugisha JK, Ssali FN, Kityo CM, Rwambuya SD, Mugerwa RD, Mmiro FA, Morrison CS, Salata RA. Namayanja GK, et al. Among authors: kityo cm. Afr Health Sci. 2005 Dec;5(4):338-40. doi: 10.5555/afhs.2005.5.4.338. Afr Health Sci. 2005. PMID: 16615847 Free PMC article.
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
Ssali F, Stöhr W, Munderi P, Reid A, Walker AS, Gibb DM, Mugyenyi P, Kityo C, Grosskurth H, Hakim J, Byakwaga H, Katabira E, Darbyshire JH, Gilks CF; DART Trial Team. Ssali F, et al. Among authors: kityo c. Antivir Ther. 2006;11(6):741-9. doi: 10.1177/135965350601100612. Antivir Ther. 2006. PMID: 17310818 Clinical Trial.
248 results